Campbell Riddick Coleman
MD Student with Scholarly Concentration in Molecular Basis of Medicine, expected graduation Spring 2030
All Publications
-
Autism spectrum disorder and mild traumatic brain injury in the pediatric population: a scoping review.
Journal of neurosurgery. Pediatrics
2026: 1-10
Abstract
OBJECTIVE: Concussions (i.e., mild traumatic brain injuries [mTBIs]) commonly produce transient neurocognitive and somatic symptoms that may overlap with baseline characteristics of neurodiverse populations. The relationship between autism spectrum disorder (ASD) and concussion/mTBI remains poorly characterized. This scoping review sought to synthesize existing literature evaluating concussion/mTBI risk, baseline neurocognitive testing, and symptom reporting in individuals with ASD.METHODS: A scoping review was conducted in accordance with PRISMA guidelines. Embase, Scopus, PubMed, Web of Science, PsycINFO, and CENTRAL databases were searched for studies evaluating ASD and concussion or mTBI. The central research question was the following: What is the current state of knowledge related to concussions/mTBI in patients with ASD? This review sought to evaluate the areas of baseline testing, acute symptomatology, injury characteristics, and recovery. Studies were required to explicitly evaluate ASD in relation to concussion/mTBI outcomes or neurocognitive testing. Studies that did not isolate ASD from other neurodevelopmental disorders, as well as reviews, editorials, and conference abstracts, were excluded.RESULTS: The search identified 374 studies, of which 7 (1.9%) met full inclusion criteria after screening. Most studies evaluated baseline neurocognitive testing using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) platform in pediatric/adolescent athletes. Three studies (42.9%) reported that individuals with ASD were more likely to produce invalid baseline neurocognitive scores and demonstrated differences in certain cognitive composites compared with controls. Two studies (28.6%) evaluated baseline concussion-like symptoms, with one reporting higher symptom endorsement among athletes with ASD and the other finding no statistically significant differences from controls. Epidemiological studies did not demonstrate a clear association between ASD and increased risk of concussion. Notably, no identified studies evaluated acute postinjury symptom trajectories or recovery outcomes following concussion in individuals with ASD.CONCLUSIONS: Existing literature examining ASD and concussion/TBI primarily evaluated baseline neurocognitive testing and suggested potential differences in testing performance and symptom reporting among individuals with ASD. However, the authors identified a critical lack of studies evaluating acute symptoms and recovery trajectories following concussion/mTBI in this population, which represents a significant barrier for clinicians-from athletic trainers to pediatricians to pediatric neurosurgeons-in accurately diagnosing, risk stratifying, and managing these patients in the postinjury setting. Prospective investigations are needed to better define concussion/mTBI presentation, recovery patterns, and optimal management strategies for individuals with ASD.
View details for DOI 10.3171/2026.5.PEDS26149
View details for PubMedID 42993965
-
Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.
Cells
2026; 15 (6)
Abstract
Glioblastoma (GBM) persists as one of the greatest challenges in the treatment of human cancer, despite extensive efforts to leverage the therapeutic potential of immunotherapy. While checkpoint blockade and other forms of immunotherapy have revolutionized the treatment of various cancers, their therapeutic efficacy in GBM has been hindered by the profound immunosuppressive environment, spatial heterogeneity, and dynamic immune metabolic challenges associated with the tumor microenvironment. In this review, we will synthesize recent advances and insights to develop a next-generation framework for GBM immunotherapy based on systems biology approaches to understanding the complex interplay between GBM and the immune system, as opposed to single-axis approaches to immune activation and modulation. We will discuss how the functional competence of the interferon system, myeloid antigen presentation status, T-cell clone status, spatial organization of the immune microenvironment, and resource competition between GBM and the immune system dictate therapeutic responsiveness. Furthermore, the current paper elucidates how recent advances in spatial transcriptomics, single-cell analysis, and high-parameter imaging enable us to understand how immune phenotype status varies across GBM regions and treatment status, and how this information can be used to develop predictive and pharmacodynamic biomarkers of therapeutic efficacy and failure. We will then discuss how these advances form the basis for rational combination approaches to GBM immunotherapy, which involve the integration of checkpoint blockade with metabolic reprogramming, myeloid modulation, and interferon system reactivation, and how artificial intelligence-based analytics and adaptive clinical trial design can guide the development of biomarker-based therapeutic selection approaches.
View details for DOI 10.3390/cells15060561
View details for PubMedID 41892350
View details for PubMedCentralID PMC13025625
-
Structural determinants of signal speed: Estimated axonal latency and its multimodal validation during face processing in autism.
bioRxiv : the preprint server for biology
2025
Abstract
It has not previously been possible to investigate the fundamental relationship between axonal structure - which dictates action potential transmission - and human neuronal function in vivo. Here, we introduce a novel metric of axonal signal speed, estimated axonal latency (EAL), derived from the relationship between axonal diameter, myelination, and length measured via MRI. We validate EAL along two pathways of the face processing network by relating it to N170 latency, an electrophysiological marker of face processing speed measured via EEG. Our results show that EAL along these pathways predicts N170 latency specifically during face processing. Moreover, we demonstrate that individuals with and without autism rely upon different pathways, potentially providing a structural account for autism-related face processing differences. By establishing this relationship between EEG-based electrical function and MRI-based axonal microstructure, we provide a non-invasive, spatially detailed estimate of neuronal processing speed that can inform our understanding of brain function, development, and disorder.
View details for DOI 10.1101/2025.03.19.644214
View details for PubMedID 40166310
View details for PubMedCentralID PMC11957106
-
Towards Comprehensive Connectivity Modeling.
Neuroinformatics
2024; 22 (3): 225-227
View details for DOI 10.1007/s12021-024-09676-4
View details for PubMedID 38926268
View details for PubMedCentralID 1794324
https://orcid.org/0009-0001-8998-8371